Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price fell 9.7% on Monday . The company traded as low as C$0.28 and last traded at C$0.28. 394,482 shares were traded during mid-day trading, a decline of 43% from the average session volume of 686,639 shares. The stock had previously closed at C$0.31.
Hemostemix Stock Down 12.9 %
The company has a market capitalization of C$23.52 million, a price-to-earnings ratio of -13.50 and a beta of 0.20. The firm has a 50 day moving average price of C$0.11 and a two-hundred day moving average price of C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- When to Sell a Stock for Profit or Loss
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- Trading Halts Explained
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- How to Invest in the Best Canadian Stocks
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
